- Home
- DOCN vs MRUS Comparison
DOCN vs MRUS Comparison
Compare DOCN & MRUS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DOCN
- MRUS
- Stock Information
- Founded
- DOCN 2011
- MRUS 2003
- Country
- DOCN United States
- MRUS Netherlands
- Employees
- DOCN N/A
- MRUS N/A
- Industry
- DOCN Retail: Computer Software & Peripheral Equipment
- MRUS Biotechnology: Pharmaceutical Preparations
- Sector
- DOCN Technology
- MRUS Health Care
- Exchange
- DOCN Nasdaq
- MRUS Nasdaq
- Market Cap
- DOCN 4.0B
- MRUS 3.6B
- IPO Year
- DOCN 2021
- MRUS 2016
- Fundamental
- Price
- DOCN $38.95
- MRUS $44.36
- Analyst Decision
- DOCN Buy
- MRUS Strong Buy
- Analyst Count
- DOCN 10
- MRUS 10
- Target Price
- DOCN $41.56
- MRUS $86.70
- AVG Volume (30 Days)
- DOCN 1.1M
- MRUS 434.2K
- Earning Date
- DOCN 11-04-2024
- MRUS 10-31-2024
- Dividend Yield
- DOCN N/A
- MRUS N/A
- EPS Growth
- DOCN N/A
- MRUS N/A
- EPS
- DOCN 0.87
- MRUS N/A
- Revenue
- DOCN $756,564,000.00
- MRUS $35,932,000.00
- Revenue This Year
- DOCN $14.25
- MRUS N/A
- Revenue Next Year
- DOCN $13.03
- MRUS $52.49
- P/E Ratio
- DOCN $44.47
- MRUS N/A
- Revenue Growth
- DOCN 12.08
- MRUS N/A
- 52 Week Low
- DOCN $26.63
- MRUS $22.26
- 52 Week High
- DOCN $44.80
- MRUS $61.61
- Technical
- Relative Strength Index (RSI)
- DOCN 46.51
- MRUS 32.24
- Support Level
- DOCN $35.71
- MRUS $42.30
- Resistance Level
- DOCN $40.23
- MRUS $53.49
- Average True Range (ATR)
- DOCN 1.69
- MRUS 2.29
- MACD
- DOCN -0.03
- MRUS -1.04
- Stochastic Oscillator
- DOCN 63.77
- MRUS 15.70
About DOCN DigitalOcean Holdings Inc.
DigitalOcean Holdings Inc is a cloud computing platform offering on-demand infrastructure and platform tools for developers, start-ups and small and medium-sized businesses. The customers use the platform for a wide range of cases, such as web and mobile applications, website hosting, e-commerce, media and gaming, personal web projects, and managed services, among many others. The group has a business presence in North America, Europe, Asia and Other countries.
About MRUS Merus N.V.
Merus NV is a clinical-stage immuno-oncology company. It develops bispecific antibody therapeutics. The company is developing full-length human multispecific antibody therapeutics, referred to as Biclonics. Merus has only reportable segment comprising the discovery and development of bispecific therapeutics. Some of its products in the pipeline include MCLA-128; MCLA-117; MCLA-158 and others.